GC Biopharma Introduces ALYGLO™ for Immune Treatment
GC Biopharma USA, Inc. is thrilled to announce the launch of its innovative immunoglobulin product, ALYGLO (immune globulin intravenous, human-stwk). This new therapy is now available for adult patients aged 17 and older who are living with primary humoral immunodeficiency (PI). This rare and chronic condition poses significant challenges, as it hampers the body’s ability to produce antibodies, making individuals more susceptible to infections.
The Importance of ALYGLO for Patients
For those diagnosed with PI, ALYGLO offers a crucial treatment option. This disorder weakens immune defenses, highlighting the urgent need for effective therapies. ALYGLO has successfully met the primary safety and efficacy benchmarks required by the FDA during rigorous Phase 3 clinical trials. A standout feature of ALYGLO is its advanced manufacturing process, which employs Cation Exchange Chromatography (CEX) to eliminate coagulation factor XIa (FXIa) to undetectable levels. The medication received FDA approval on Dec. 15, 2023.
Insights from Dr. Eun Chul Huh
Dr. Eun Chul Huh, President and CEO of GC Biopharma, underscores the significance of this launch, calling it a historic milestone. "The US launch of ALYGLO demonstrates our commitment to improving the health and lives of individuals facing rare diseases worldwide," he remarked. This initiative reflects GC Biopharma's dedication to investing in research and development to create future products that will make a positive difference in the US healthcare system.
Patient Access Through a Distribution Network
ALYGLO will be made available to patients and healthcare professionals through a carefully chosen limited distribution network of top national Specialty Pharmacy providers. This approach ensures broad accessibility, which is vital for those diagnosed with primary immune deficiencies. Additionally, ALYGLO can also be obtained through specialty distributors throughout the United States.
Comments from Dr. Lisa Betts
Dr. Lisa Betts, Chief Operating Officer for GC Biopharma USA, Inc., shared her excitement: "ALYGLO greatly expands treatment options, improving access in the US marketplace. Our mission is to provide life-saving therapies to individuals with rare diseases, and we are delighted to introduce another immune globulin therapeutic alternative for patients."
Understanding Primary Humoral Immunodeficiency (PI)
Primary Humoral Immunodeficiency (PI) includes various disorders that hinder the body’s ability to produce sufficient antibodies. This deficiency results in a heightened risk of infections, particularly bacterial ones that affect the respiratory and gastrointestinal systems. The conditions treated by ALYGLO encompass congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies, all of which highlight the urgent need for effective treatment options.
About ALYGLO
ALYGLO is a 10% solution of immunoglobulin G designed for intravenous infusion, derived from pooled human plasma. The comprehensive production process includes essential steps to minimize the risk of virus transmission, such as fractionation, solvent/detergent treatment, and nanofiltration. The incorporation of advanced CEX technology during manufacturing further ensures the removal of FXIa, enhancing overall safety.
About GC Biopharma Corp.
With over 50 years of experience, GC Biopharma Corp. (formerly known as Green Cross Corporation) is a leader in the biopharmaceutical industry, providing essential protein therapeutics and vaccines. Based in Yongin, South Korea, GC Biopharma is committed to delivering quality healthcare solutions on a global scale.
About GC Biopharma USA, Inc.
Established in 2018 in Teaneck, NJ, GC Biopharma USA, Inc. focuses on sales, marketing, and business strategies to support patients and healthcare providers across the US. Leveraging the extensive expertise of its parent company, GC Biopharma USA aims to expand its reach and offer world-class plasma therapies and vaccines.
Frequently Asked Questions
What is ALYGLO used for?
ALYGLO is used to treat primary humoral immunodeficiency in adults, helping to enhance the body’s ability to fight infections.
How is ALYGLO manufactured?
ALYGLO is manufactured using advanced techniques, including Cation Exchange Chromatography, to ensure both safety and efficacy.
Who can prescribe ALYGLO?
ALYGLO can be prescribed by qualified healthcare professionals for adult patients diagnosed with primary humoral immunodeficiency.
What safety information should I know about ALYGLO?
Key safety information includes the potential for allergic reactions and the necessity for monitoring during infusion. Patients should discuss any concerns with their healthcare provider.
How can patients obtain ALYGLO?
Patients can obtain ALYGLO through a limited distribution network of national Specialty Pharmacy partners and specialty distributors throughout the United States.
